% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • bendestre bendestre Apr 7, 2013 12:28 PM Flag

    The history of this biotech masquerade part 1

    This is the history of this masquerade:
    In April 2012 a company named AVI BioPharma reports results of a 24 weeks Phase 2 double blind randomized placebo controlled trial in 12 DMD patients. The study shows a 22% increase in dystrophin levels as compared only in the lowest eteplirsen treated group (30mg) but not 50 mg. Supposedly 50 mg dystrophin levels were only measured at 12 weeks but we don’t know why. Importantly the study show’s no increase in 6 minute walk distance for treated patients as compared to placebo. AVI stock goes nowhere after release of the data.
    In July 2012 the company changes its name to Sarepta. Same company, same product, same data.
    In October 2012 Sarepta management introduces the concept of Modified Intent To Treat to analyze the data. May be they should also have changed their name to MAVI (Modified AVI), because this is what Sarepta is.
    The key aspect of the modified analysis is that they now drop two of the 8 patients in the treated group who had a dramatic decline in walk ability following initiation of treatment with eteplirsen. By doing so the study now starts to look positive. It’s a miracle!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.98-0.02(-0.15%)3:23 PMEDT